NEWARK, N.J., July 21 /PRNewswire-FirstCall/ -- BioNeutral Group, Inc. ("BioNeutral") (OTC Bulletin Board: BONU), a specialty chemical technology based Life Science Company announced today that at ATS Labs using the required EPA protocol testing, BioNeutral's Ygiene(TM) Hospital Grade Antimicrobial passed the difficult Quantitative Disk Carrier test by totally eradicating all 5.4 million spores of Clostridium difficile (C.diff) present in this test in 10 minutes at room temperature. Few antimicrobials are capable of passing this test. These Validated Results Now Give Ygiene(TM) Antimicrobial Unique Performance Status Among All Disinfectants.
Clostridium difficile (C.diff) is the most difficult to eliminate spore form of health threatening microorganisms present in most health care facilities globally. Many leading commercially available antimicrobials currently used in the global health care arena are ineffective at eliminating Clostridium difficile spores. This is one reason why hospital acquired infections (HAI) are such a serious and growing problem. In the USA alone about 2 million patients annually are afflicted with hospital acquired infections (HAI) resulting in approximately 100,000 deaths. Worldwide hospital acquired infections are on the rise and will lead to hundreds of thousands of needless deaths annually. BioNeutral's Ygiene(TM) Hospital Grade Antimicrobial will be a significant part of the future solution for controlling hospital acquired infections in general and the expedient total restoration of areas found to be contaminated with Clostridium difficile (C.diff). Currently health care facilities globally have severely limited options for eliminating this dangerous spore.
Chief Scientist for BioNeutral Group, Inc., Dr. Andy Kielbania stated, "These independent ATS Labs test results completely validate our internal product development effort
|SOURCE BioNeutral Group, Inc.|
Copyright©2009 PR Newswire.
All rights reserved